Quick answers
- What is Sodium polystyrene sulfonate used for?
- The FDA-approved label (Kionex, ANI Pharmaceuticals, Inc., September 19, 2025) says: “Kionex Suspension is indicated for the treatment of hyperkalemia.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Sodium polystyrene sulfonate have a boxed warning?
- No. None of the 15 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Sodium polystyrene sulfonate?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Sodium polystyrene sulfonate been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Sodium polystyrene sulfonate?
- 11 companies list prescription products of Sodium polystyrene sulfonate in the FDA NDC Directory, including Bryant Ranch Prepack, CMP Pharma, Inc. and Atlantic Biologicals Corp..
What Sodium polystyrene sulfonate is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Kionex Suspension is indicated for the treatment of hyperkalemia.
— FDA label: Kionex, ANI Pharmaceuticals, Inc., effective September 19, 2025. Read the full label on DailyMed →
The FDA has 15 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 15 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Powder, for suspension · Suspension · Powder |
|---|---|
| Route | Oral · Rectal |
| Prescription products | 16 in the FDA NDC Directory |
| Brand names | Kionex |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| sodium polystyrene sulfonate 100% powder | Generic | $0.0926–$0.4823 per gram 2 packages, lowest to highest |
| sodium polystyrene sulfonate 100% powder, for suspension | Generic | $0.0926 per gram |
| sodium polystyrene sulfonate 15 g/60 mL suspension | Generic | $0.3851–$0.4385 per mL 2 packages, lowest to highest |
| sodium polystyrene sulfonate 15 g/60 mL suspension | Brand: Kionex | $0.3132 per mL |
| sodium polystyrene sulfonate 4.1 meq/g powder, for suspension | Generic | $0.0926–$0.4823 per gram 7 packages, lowest to highest |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack5 products
- CMP Pharma, Inc.2 products
- Atlantic Biologicals Corp.1 product
- Epic Pharma, LLC1 product
- Chartwell RX, LLC1 product
- KVK-Tech, Inc.1 product
- Burel Pharmaceuticals, LLC1 product
- Cardinal Health 107, LLC1 product
- ANI Pharmaceuticals, Inc.1 product
- Sunrise Pharmaceutical, Inc.1 product
- PuraCap Laboratories LLC1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (8)
- ANDA087859Cmp Pharma Inc · December 8, 1982
- ANDA089910Cmp Pharma Inc · January 19, 1989
- ANDA040028Ani Pharms · September 17, 2007
- ANDA040905Kvk Tech · March 30, 2009
- ANDA202333Epic Pharma LLC · March 19, 2014
- ANDA204071Nuvo Pharms Inc · November 28, 2014
- ANDA206815Chartwell Rx · February 18, 2016
- ANDA214912Lyne · June 10, 2025
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 313072, 793741, 2101899 |
|---|---|
| SPL set ID of the quoted label | 676c3d81-d575-43f6-8748-e04b7c0cafeb |
| FDA labels (SPL) | 15 |
| FDA applications | 8 ANDA |
| Active ingredients (FDA) | SODIUM POLYSTYRENE SULFONATE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Kionex, ANI Pharmaceuticals, Inc., effective September 19, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →